October 3rd 2024
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses challenges of integrating bispecific antibodies and CAR T-cell therapies into the community for myeloma.
October 1st 2024
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the efficacy of daratumumab plus VRd in patients with transplant-ineligible or -deferred multiple myeloma.
April 22nd 2024
Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.
April 15th 2024
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the risk-benefit profile of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.
April 10th 2024
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the optimal role for ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.
April 6th 2024
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the FDA approval of cilta-cel for relapsed/refractory multiple myeloma.
February 19th 2024
The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.
A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.
February 12th 2024
The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.
Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.
February 5th 2024
Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.
Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.
January 29th 2024
An expert panel reviews recent updates on BCMA-targeting bispecific antibodies in multiple myeloma.
Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.
January 22nd 2024
A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.
The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.
January 19th 2024
Dr. Usmani, MD, MBA, FACP provides insights into Selinexor's safety profile in Relapsed/Refractory Multiple Myeloma (R/R MM), comparing it with other treatments and delve into the ongoing challenges and unmet needs in R/R MM patient care.
An expert explores factors influencing the selection of treatment regimens in relapsed, triple class refractory multiple myeloma (MM) patients, with a focus on prophylactic measures for managing adverse events associated with novel agents like Selinexor, bispecific, and CAR-T therapies.
January 15th 2024
Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.
Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.